Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05201781 · ClinicalTrials.gov registry record · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
A Phase 4 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 295
- Enrollment target
- 20
- Study locations
NCT05201781 is a Phase 4 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 295 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT05201781, a Phase 4 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 295 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Conditions Studied
Interventions
- DRUG Cilta-cel
Study Locations (20)
California
- City of Hope - Duarte
- University of California San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Massachusetts
- Dana Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Boston
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
New Jersey
- Hackensack University Medical Center - Hackensack
- Rutgers Cancer Institute of New Jersey - New Brunswick
New York
- Roswell Park Cancer Institute - Buffalo
- Mount Sinai Medical Center - New York
Arizona
- Mayo Clinic Cancer Center-Scottsdale - Phoenix
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2037-10-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05201781
The ClinicalTrials.gov registry entry for NCT05201781 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (46% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Cilta-cel is the first listed.
NCT05201781 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Massachusetts, Illinois.
Frequently Asked Questions
What is clinical trial NCT05201781 about?
NCT05201781 is a clinical study titled "A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel". The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
What is the current status of trial NCT05201781?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 295 participants. The study started on 2022-03-09. Estimated completion is 2037-10-30.
What conditions does trial NCT05201781 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05201781?
The interventions under investigation include: Cilta-cel (DRUG).
Who is sponsoring clinical trial NCT05201781?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05201781 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
RECRUITING · Phase 4
-
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
RECRUITING · Phase 4
-
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
ACTIVE NOT RECRUITING · Phase 4
-
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
COMPLETED · Phase 4
-
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
COMPLETED · Phase 4
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.